Correlation of the chemotherapy reply and overall survival in patients with non-small ß-cell lung cancer with biological markers through the genotypic analysis and protein expression

• Grant number: 09/52574-5
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2010
• End date: August 31, 2012
• Field of knowledge: Biological Sciences - Genetics
• Principal Investigator: Lair Zambon
• Grantee: Lair Zambon
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Unhappily, in most cases of lung cancer (LC), the diagnosis is delayed, what explains, in part, its dark prognostic. In this phase, the therapeutically used is chemotherapy and radiotherapy. The conventional reply to chemotherapy does not exceed 30%. The heterogeneity of chemotherapy reply shows that previous molecular identification, of these patients, would be very important for this therapeutically modality. The objective of this study is to analyze 100 patients with non-small- cell lung cancer, without previous treatment, carrying through genotyping analysis (PCR-RFLP, PCR-SSCP and automated DNA sequencer) and of protein expression (immunohistochemically). The understanding of these findings will help, in clinical practice, the treatment of the lung cancer through the chemotherapy and the prognostic markers, optimizing resources. This analysis will be important to improve the overall survival. Statistical analysis will be performed using X2 test or Fisher's exact test and to calculate survival rates the Kaplan-Meier method will be used. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

HONMA, HELEN N.; PERROUD, JR., MAURICIO W.; LEME, MAURICIO S. T.; BARBEIRO, ARISTOTELES S.; SAAD, BRUNA A.; MORCILLO, ANDRE M.; VASSALLO, JOSE; COSTA, DANIEL B.; ZAMBON, LAIR. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. TARGETED ONCOLOGY, v. 9, n. 4, p. 389-394, DEC 2014. (09/52574-5)

HONMA, HELEN NAEMI; PERROUD, JR., MAURICIO WESLEY; MORCILLO, ANDRE MORENO; VASSALLO, JOSE; ZAMBON, LAIR. Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression. Jornal Brasileiro de Pneumologia, v. 44, n. 3, p. 245-246, MAY-JUN 2018. (09/52574-5)